ERCC1 as a marker of prognosis and sensitivity to platinum-based chemotherapy in patients with stage III–IV non-small cell lung cancer
DOI:
https://doi.org/10.14739/2310-1237.2020.1.203639Keywords:
non-small cell lung cancer, prognostic factors, predictive markers, ERCC1, survivalAbstract
Lung cancer is one of most actual problem of modern oncology. The III-IV stages of non-small cell lung cancer (NSCLC) in Zaporizhzhia region are diagnosed in more than 75 % of patients. Chemotherapy is a standard of advanced NSCLC treatment. But results of such treatment are still unsatisfactory due to tumoral chemoresistance. So, it's very important question to search for new clinical factors with significant prognostic and predictive value.
Objective. To evaluate the expression of ERCC1, p53 in patients at advanced stages of NSCLC, to examine the association of marker expression with various clinical and morphological factors, and to evaluate the prognostic and predictive value of ERCC1 in patients at advanced stages of NSCLC.
Methods. 45 patients with IIIA, IIIB, IV stages of NSCLC were included in this study. ERCC1 was assessed by immunohistochemistry. According to received data relationship of ERCC1 expression with clinico-morphological factors and ERCC1 clinical significance were assessed.
Results. Clinically significant relation of ERCC1 expression with stage and p53 expression was observed in our study. It was revealed that patients with high ERCC1 expression had better survival than patients with low ERCC1 expression (106.5 vs 38 weeks, P = 0.002). It was also mentioned that using of platinum-based chemotherapy greatly improved patients’ survival. ERCC1, p53 and stage disease were proved to be as independent prognostic factors in patients which received chemotherapy.
Conclusions. ERCC1 is important prognostic factor and could be used to determine efficacy of platinum-based chemotherapy in patients with the IIIA–IV stages of NSCLC.
References
Ukrainian cancer registry statistics. (2016). Rak v Ukraini, 2014-2015. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2014-2015. Occupation, death, demonstration of oncological service]. Bulletin of National Cancer Registry of Ukraine, 17. [in Ukrainian].
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., Peters, S., & Comm, E. G. (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29, 192-237. https://doi.org/10.1093/annonc/mdy275
Xu, Y., Xu, Z., Li, Q., Guo, L., Wang, Y., Zhou, J. C., Wang, G. S., & Liu, Y. L. (2019). Mutated p53 Promotes the Symmetric Self-Renewal of Cisplatin-Resistant Lung Cancer Stem-Like Cells and Inhibits the Recruitment of Macrophages. Journal of Immunology Research, 2019, Article 7478538. https://doi.org/10.1155/2019/7478538
Perez-Ramirez, C., Canadas-Garre, M., Molina, M. A., Robles, A. I., Faus-Dader, M. J., & Calleja-Hernandez, M. A. (2017). Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutation Research-Reviews in Mutation Research, 771, 32-58. https://doi.org/10.1016/j.mrrev.2016.11.003
Iglesias, V. S., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018). Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? Frontiers in Oncology, 8, Article 267. https://doi.org/10.3389/fonc.2018.00267
Han, Y. L., Liu, J., Sun, M. L., Zhang, Z. P., Liu, C. Y., & Sun, Y. P. (2016). A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis. Disease Markers, Article 7643981. https://doi.org/10.1155/2016/7643981
Macerelli, M., Ganzinelli, M., Gouedard, C., Broggini, M., Garassino, M. C., Linardou, H., Damia, G., & Wiesmuller, L. (2016). Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treatment Reviews, 48, 8-19. https://doi.org/10.1016/j.ctrv.2016.05.004
Taieb, J., Jung, A., Sartore-Bianchi, A., Peeters, M., Seligmann, J., Zaanan, A., Burdon, P., Montagut, C., & Laurent-Puig, P. (2019). The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs, 79(13), 1375-1394. https://doi.org/10.1007/s40265-019-01165-2
Sacco, J. J., Al-Akhrass, H., & Wilson, C. M. (2016). Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer. Current Pharmaceutical Design, 22(28), 4374-4385. https://doi.org/10.2174/1381612822666160603014932
Mao, Q. X., Dong, G. C., Xia, W. J., Yin, R., Jiang, F., Xu, L., Qiu, M. T., & Chen, Q. (2015). Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy A Prisma-Compliant Meta-Analysis. Medicine, 94(39), Article e1593. https://doi.org/10.1097/md.0000000000001593
Fromowitz, F. B., Viola, M. V., Chao, S., Oravez, S., Mishriki, Y., Finkel, G., Grimson, R., & Lundy, J. (1987). Ras p21 Expression in the progression of breast cancer. Human Pathology, 18(12), 1268-1275. https://doi.org/10.1016/s0046-8177(87)80412-4
Lord, R. V. N., Brabender, J., Gandara, D., Alberola, V., Camps, C., Domine, M., Cardenal, F., Sanchez, J. M., Gumerlock, P. H., Taron, M., Sanchez, J. J., Danenberg, K. D., Danenberg, P. V., & Rosell, R. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clinical Cancer Research, 8(7), 2286-2291.
Olaussen, K. A., & Postel-Vinay, S. (2016). Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Annals of Oncology, 27(11), 2004-2016. https://doi.org/10.1093/annonc/mdw321
Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127(3), 978-983. https://doi.org/10.1378/chest.127.3.978
Tsao, M. S., Aviel-Ronen, S., Ding, K., Lau, D., Liu, N., Sakurada, A., Whitehead, M., Zhu, C. Q., Livingston, R., Johnson, D. H., Rigas, J., Seymour, L., Winton, T., & Shepherd, F. A. (2007). Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. Journal of Clinical Oncology, 25(33), 5240-5247. https://doi.org/10.1200/jco.2007.12.6953
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
